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(57) ABSTRACT 
Systems and methods for analyzing and predicting treatment 
outcomes of medical procedures such as vascular interven-
tions and reconstructions are disclosed. An illustrative system 
for analyzing and predicting therapeutic outcomes of medical 
procedures comprises a relational database configured for 
classifying and storing patient specific input data for multiple 
patients, a fluid-solid interaction biomechanical model con-
figured for performing a biomechanics simulation and gen-
erating biomechanics data, and a graphical user interface. 
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MODEL-BASED SYSTEMS AND METHODS 
FOR ANALYZING AND PREDICTING 
OUTCOMES OF VASCULAR 
INTERVENTIONS AND RECONSTRUCTIONS 
CROSS-REFERENCE TO RELATED 
APPLICATION 
[0001] This application claims priority to U.S. Provisional 
Application No. 611387,775, entitled "Method For Selection 
of Patches For use In Vascular Interventions and Reconstruc-
tions," filed on Sep. 29, 2010, the contents of which are 
incorporated herein by reference in their entirety for all pur-
poses. 
STATEMENT REGARDING FEDERALLY 
SPONSORED RESEARCH OR DEVELOPMENT 
[0002] This invention was made with government support 
under NSF grant EPS-0701892. The government has certain 
rights in the invention. 
TECHNICAL FIELD 
[0003] The present disclosure relates generally to systems 
and methods for analyzing and predicting outcomes of vas-
cular interventions, reconstructions, and other medical pro-
cedures. 
BACKGROUND 
[0004] Cardiovascular disease is the failure of the circula-
tory system to supply adequate amounts of blood to organs 
and tissue. Cardiovascular disease affects more than eighty 
million people in the United States alone, and is the single 
leading cause of death and disability for both men and women 
in the developed world. In many cases, cardiovascular disease 
is caused by atherosclerosis, or the narrowing of the arteries 
due to fatty build ups called atheromatous plaques. These 
plaques can also include scar tissue, cholesterol, calcium, and 
other substances contained in the blood. 
[0005] In severe cases of the disease, reestablishment of 
blood flow in narrowed or blocked arteries can only be 
achieved with vascular interventions and reconstructions. 
Among blood vessels frequently repaired are the carotid, 
aortoilliac, peripheral, mesenteric, renal, and arm arteries. 
The surgical and interventional procedures used to treat 
severely affected blood vessels can be classified as either 
open or endovascular surgery. The former can be in the form 
of a bypass surgery involving synthetic or natural grafts or an 
endarterectomy procedure in which the atherosclerotic 
plaque is surgically removed through an incision on the side 
of the blood vessel. Endarterectomy procedures often involve 
the use of a patch of natural or synthetic material to close the 
incision formed in the vessel wall in order to maintain proper 
blood flow. Angioplasty is a minimally invasive, catheter-
based vascular technique in which a small balloon is inflated 
inside a narrowed blood vessel, opening up the vessel for 
improved blood flow. After the angioplasty, a mesh-like stent 
is frequently deployed in the vessel to maintain long-term 
patency of the vessel after the procedure. 
[0006] Other vascular diseases that can be treated with 
surgical procedures involving vascular grafts include 
abdominal and thoracic aortic aneurysms and peripheral arte-
rial aneurysms (e.g., poplietal, femoral, carotid, arm, or vis-
ceral aneurysms). For aortic aneurysms, synthetic or natural 
grafts are typically used in the repair of the affected vessels. 
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For peripheral aneurysms, bypass or replacement procedures 
are typically used. Endovascular stent -grafts or covered stents 
are sometimes used in the minimally invasive treatment of 
aneurysms. 
[0007] Many of the treatment techniques used for treating 
cardiovascular disease have been shown to increase life 
expectancy and decrease the length of hospitalization and 
postoperative care. For example, endarterectomy procedures 
used for treating the carotid artery have been shown to reduce 
the risk of stroke in patients with moderate and high-grade 
symptomatic and high-grade asymptomatic carotid bifurca-
tion stenoses. Cartoid endarterectomy followed by patch 
angioplasty has also been shown to decrease the incidence of 
early and late complications associated with the performance 
of carotid endarterectomy. A variety of synthetic and biologi-
cal patches have been developed and are available for endar-
terectomy procedures. Alternatively, a variety of stents and 
stent-graft are also available. 
[0008] One complication associated with some surgical 
and interventional procedures is the postoperative restenosis 
of the reconstructed vessel. Restenosis often starts as neoin-
timal hyperplasia or abnormal growth of new tissue over or 
near the graft or stent. This is often followed by new athero-
sclerotic plaque build-up near or inside the graft or stent. 
Restenosis affects as many as 20 to 30 percent of all arterial 
reconstructions, and in some instances can affect a greater 
percentage of patients depending on the type of blood vessel 
being repaired and the characterization of the restenosis. Both 
neointimal hyperplasia and atherosclerosis have been linked 
to various forms of insult to the arterial wall. Such insult may 
be produced by the increased stresses and injury in recon-
structed or treated blood vessels or by the atherogenic influ-
ence of the flow and oscillatory wall shear stress in the blood 
flow. Another possible complication is the mechanical failure 
of stents or stent-grafts. 
[0009] The mechanical factors leading to restenosis or 
device failure caunot be imaged or measured using existing 
experimental techniques. However, they can be predicted 
using biomechanics modeling. The problem of accurately 
predicting these disease-related mechanical and flow factors 
in surgically repaired blood vessels is a complex non-linear 
fluid-solid interaction problem. The outcomes highly depend 
on the large number of inputs and data that are known to vary 
broadly based on the individual characteristics of the patient, 
stage and type of disease, and multiple other conditions. 
Currently, there are no known systems or methods to system-
atically evaluate, visualize, and optimize these mechanical 
and flow factors as a result of the reconstruction or treatment. 
Such optimization, however, could decrease the incidence of 
neointimal hyperplasia and atherosclerosis by selecting an 
appropriate medical device or a suitable course of treatment 
for a particular patient or group of patients. The optimization 
based on predictive modeling could also lead to new and 
improved repair materials and devices. 
SUMMARY 
[0010] The present disclosure relates generally to model-
based systems and methods for analyzing and predicting out-
comes of vascular interventions, reconstructions, or other 
medical procedures. 
An illustrative method for analyzing and predicting treatment 
outcomes of vascular interventions and reconstructions com-
prises: inputting patient specific data associated with a patient 
into a database; searching the database and obtaining addi-
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tional data to be associated with the patient, wherein the 
additional data is obtained based at least in part on patient 
specific data stored within the database for one or more other 
patients; selecting at least one of a treatment parameter or 
medical device parameter to be used in association with a 
proposed treatment option for treating the patient; searching 
the database and obtaining one or more model properties 
associated with the treatment or medical device parameter; 
generating a fluid-solid interaction biomechanical model 
based at least in part on the patient specific data, the additional 
data associated with the patient, and the model properties; 
performing a biomechanics simulation and generating bio-
mechanics data using the biomechanical model; and analyz-
ing the biomechanics data. 
[0011] An illustrative system for analyzing and predicting 
therapeutic outcomes in medical procedures comprises: a 
relational database configured for classifYing and storing 
patient specific input data for a plurality of patients; a means 
for obtaining and inputting patient specific input data to the 
database; a means for selecting additional data to be associ-
ated with the patient in the database; a means for inputting 
treatment related and medical device related parameters to the 
database; a means for selecting treatment type, inputting 
model parameters, and assembling a biomechanical model 
based on the selected treatment type, the patient specific data, 
the additional data associated with the patient, and the treat-
ment and medical device related parameters; a processor and 
fluid-solid interaction biomechanical model configured for 
performing a biomechanics simulation and generating bio-
mechanics data, the fluid-solid biomechanical model com-
prising time-dependent, three-dimensional solid and fluid 
equations; a means for evaluating the outcomes of the biome-
chanics simulation; and an interface configured for exchang-
ing data between the database and a plurality of users. 
[0012] While multiple embodiments are disclosed, still 
other embodiments of the present invention will become 
apparent to those skilled in the art from the following detailed 
description, which shows and describes illustrative embodi-
ments of the invention. Accordingly, the drawings and 
detailed description are to be regarded as illustrative in nature 
and not restrictive. 
BRIEF DESCRIPTION OF THE DRAWINGS 
[0013] The patent or application file contains at least one 
drawing executed in color. Copies of this patent or patent 
application publication with color drawing(s) will be pro-
vided by the Office upon request and payment of the neces-
sary fee. 
[0014] FIG. 1 is a schematic view of a model-based system 
for analyzing and predicting outcomes of vascular interven-
tions and reconstructions in accordance with an illustrative 
embodiment; 
[0015] FIG. 2 is a schematic view showing several example 
input parameters for use by the mechanical properties evalu-
ation module of FIG. 1 in analyzing biological materials and 
anatomical structures; 
[0016] FIG. 3 is a schematic view showing several example 
input parameters for use by the mechanical properties evalu-
ation module of FIG. 1 in analyzing the behavior of synthetic 
grafts; 
[0017] FIG. 4 is a schematic view showing several example 
input parameters for use by the mechanical properties evalu-
ation module of FIG. 1 in analyzing the behavior of stents; 
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[0018] FIG. 5 is a schematic view showing several example 
input parameters for use by the blood rheology evaluation 
module of FIG. 1 in analyzing rheological behavior of blood; 
[0019] FIG. 6 is a schematic view showing several example 
input parameters for use by the blood vessel geometry evalu-
ation module of FIG. 1 in analyzing the geometry of blood 
vessels or vessel reconstructions; 
[0020] FIG. 7 is a schematic view showing several example 
input parameters for use by the medical device geometry 
evaluation module of FIG. 1 in analyzing the geometry of 
medical devices such as grafts and stents; 
[0021] FIG. 8 is a schematic view showing several example 
input parameters for use by the boundary blood flow evalua-
tion module of FIG. 1 in analyzing blood flow; 
[0022] FIG. 9 is a schematic view showing several example 
input parameters for use by the load evaluation module of 
FIG. 1 in analyzing dynamic and static loads exerted on blood 
vessels, reconstructions, or other anatomical structures; 
[0023] FIGS. lOa-lOb are example plots showing posterior 
and anterior three-dimensional visualizations of blood vessel 
stresses that can be generated by the graphical user interface 
of FIG. 1; 
[0024] FIG. 11 is a schematic view showing an example 
software platform for use with the system of FIG. 1; 
[0025] FIG. 12 is a flow diagram of an example method for 
analyzing and predicting treatment outcomes of vascular 
interventions and reconstructions; 
[0026] FIG. 13 is a flow diagram of another example 
method for analyzing and predicting treatment outcomes of a 
medical procedure such as a patch endarterectomy procedure; 
[0027] FIG. 14 is a flow diagram of an example method for 
analyzing a medical device design for a group of patients; 
[0028] FIG. 15 is a flow diagram of an example method for 
analyzing a medical device design for a specific patient; 
[0029] FIG. 16 is a schematic view of three-dimensional 
mean carotid artery geometry generated for a group of sixteen 
patients; 
[0030] FIGS. 17a-17e are several plots showing the com-
parison of different surgical reconstruction techniques in 
terms of atherosclerosis-related mechanical parameters such 
as effective stress expressed in logarithmic values; 
[0031] FIG. 18a-18b are several plots showing complex, 
three-dimensional pulsatile velocity profiles in an internal 
carotid artery (lCA) and external carotid artery (ECA) , 
respectively; 
[0032] FIGS. 19a-19b are several plots showing zones of 
blood flow recirculation and stagnation in a carotid bulb for 
systole and diastole, respectively; 
[0033] FIGS. 20a-20b are several plots showing a three-
dimensional visualization of overlapping stents deployed in a 
superficial femoral artery, in which high stress concentrations 
are shown on the arterial wall along with the presence of 
atherosclerotic plaque; 
[0034] FIGS. 21a-21b are several plots showing the three-
dimensional visualization of a carotid artery before and after 
angioplasty and stenting, respectively; and 
[0035] FIGS. 22a-22b are several plots showing the pres-
ence of zones of high stress concentrations in the arterial wall, 
plaque, and stent struts. 
[0036] While the invention is amenable to various modifi-
cations and alternative forms, specific embodiments have 
been shown by way of example in the drawings and are 
described in detail below. The intention, however, is not to 
limit the invention to the particular embodiments described. 
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On the contrary, the invention is intended to cover all modi-
fications, equivalents, and alternatives falling within the 
scope of the invention as defined by the appended claims. 
DETAILED DESCRIPTION 
[0037] Model-based systems and methods that utilize 
patient-specific physiological data and/or previously 
acquired data from other, similarly situated patients or cases 
can be used to analyze, and in some cases predict, various 
parameters for determining a suitable course of treatment for 
a patient. These systems and methods can also be used as a 
tool for selecting medical devices tailored to a patient's par-
ticular medical condition, or for developing new medical 
devices. In some embodiments, the patient-specific and/or 
previously acquired input data can be classified and stored in 
one or more computer databases that can be accessed by 
individuals over a computer or computer network. For 
example, the database or databases can be accessed by health 
care professionals over the Internet to perform preoperative 
or intraoperative evaluations of possible treatment options 
and/or to optimize a particular treatment plan, thus improving 
the clinical decision-making process and overall treatment 
outcome decisions. The database can also be used by medical 
device developers for researching and developing new medi-
cal devices and treatments. 
[0038] In certain embodiments, the systems and methods 
can be used in open or endovascular surgery procedures in the 
treatment of cardiovascular diseases, including coronary 
artery disease, carotid artery disease and aortoilliac, periph-
eral, mesenteric, renal, and arm artery stenoses. The systems 
and methods can also be used in the treatment of various 
forms of arterial aneurysms, including abdominal and tho-
racic aortic aneurysms and peripheral arterial aneurysms 
(e.g., poplietal, femoral, carotid, arm, or visceral aneurysms) 
treated by repair, bypass, replacement, or endovascular stent-
grafting. The systems and methods can also be used for devel-
oping new medical devices, or for developing medical 
devices customized for use in a particular patient or groups of 
patients. 
[0039] The systems and methods disclosed herein can be 
implemented in hardware, software, or a combination of both. 
In some embodiments, the systems and methods can be 
executed as computer readable instructions on a program-
mable computer or processor comprising a data storage sys-
tem with volatile and/or non-volatile memory. Although vari-
0us example systems and methods are described herein with 
respect to vascular interventions and reconstructions, the sys-
tems and methods can be used to analyze and model other 
types of physiological conditions and can be used to evaluate 
other treatment options or to develop other types of medical 
devices. In some cases, the systems and methods can also be 
used to evaluate and predict possible medical device failures. 
[0040] FIG. 1 is a schematic view of a model-based system 
10 for analyzing and predicting outcomes of vascular inter-
ventions and reconstructions in accordance with an illustra-
tive embodiment. The system 10 comprises a relational data-
base 12 and an evaluation unit 14 operable on a computing 
device 16 such as a server, personal computer, or hand-held 
computing device. In some embodiments, the computing 
device 16 includes software and/or hardware functionality 
capable of executing various computer instructions via a pro-
cessor 18. Although the database 12 and evaluation unit 14 are 
shown as part of a single, integral computing device 16 in 
FIG. 1, in other embodiments one or more components of the 
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system 10 can be distributed across multiple computing 
devices or can be combined into a single unit. 
[0041] The database 12 is configured to store data inputted 
to the system 10 by one or more users 20, 30. In some 
embodiments, for example, the database 12 is configured to 
store raw and/or processed data associated with a group of 
current patients 22 to be treated or other individuals 24 such 
as past patients or cadavers. For example, the database 12 can 
be configured to store data obtained from an imaging proce-
dure such as Magnetic Resonance Angiography (MRA) or 
Computerized Tomographic Angiography (CTA). The data-
base 12 can also be configured to store simultaneous electro-
cardiogram (ECG) recordings, recordings of blood flow 
evaluations and other physiologic data acquired from the 
patients 22, 24. Examples of velocity data to be stored in the 
database and an example three-dimensional graphical repre-
sentation of such data is shown, for example, in FIGS. 18a-
18b. Data relating to mechanical properties of materials such 
as blood vessel wall plaque and properties of patching mate-
rials, stents and/or stent-grafts can also be collected and 
inputted as data to the database 12. 
[0042] Other input data such as patient age, gender, race, 
cardiovascular risk factor profile, clinical history, medica-
tions, blood count, diet, lifestyle, as well as other clinical 
laboratory measurements can also be inputted to and stored 
within the database 12. Typically, the type and format of the 
information inputted to the database 12 will vary depending 
on the type of patient, the patient's condition, the treatment 
options available for treating the patient, as well as other 
factors. In some embodiments, the database 12 contains aver-
age parameters computed for a particular patient or group of 
patients. In some embodiments, for example, the database 12 
contains mean three-dimensional geometric data of a particu-
lar type of vessel (e.g., a carotid artery) computed from mul-
tiple patients. 
[0043] The database 12 is expandable and scalable, allow-
ing for the addition of new data such as tissue histology, tissue 
models, medical devices, and newly discovered medical 
record data. In some embodiments, the database 12 is imple-
mented using a combination of relational and non-relational 
database schemas, allowing disparate data formats inputted 
by the users 20, 30 to be integrated into a unified database 12 
that can be accessed by other system users 20, 30. 
[0044] In the embodiment of FIG. 1, the database 12 and 
evaluation unit 14 are accessible by one or more users 20 over 
a network interface 26 with multiple network access portals 
28. In certain embodiments, for example, the network access 
portals 28 comprise Internet or intranet portals that can be 
accessed by users 20 over a computer. The database 12 and 
evaluation unit 14 canalso be accessed directly (e.g., off-line) 
by some users 30 such as software end-users or a network 
administrator. The level of database access and functionality 
may vary depending on the type of user 20,30. For example, 
users 20, 30 such as health care professionals may be pro-
vided with security credentials greater than other users 20, 30, 
allowing these professionals to access confidential informa-
tion about a specific patient or group of patients 22, 24. In 
contrast, other users 20, 30 such as researchers or medical 
device developers may be given more limited access creden-
tials to the database 12 in order to maintain patient confiden-
tiality and anonymity. 
[0045] The processor 18 is configured to run an algorithm 
or routine that combines data acquired from one or multiple 
evaluation modules 32 and generates various output param-
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eters that can be used by the processor 18 and a biomechanical 
model 31 to analyze, and in some cases predict, various 
patient-based treatment outcomes associated with the use of a 
particular reconstruction technique or medical device. In the 
embodiment of FIG. 1, the algorithm or routine comprises a 
coupled fluid-solid interaction biomechanical model 31 that 
uses, as model inputs, data that is measured and/or gathered 
by one or more of the evaluation modules 32. Based on these 
model inputs, the biomechanical model 31 determines one or 
more parameters associated with a blood vessel under evalu-
ation or in the selection of a particular medical device for use 
in treating a patient or group of patients. In certain embodi-
ments' for example, the biomechanical model 31 uses input 
data obtained across several of the evaluation modules 32 to 
better understand the current condition of a patient's blood 
vessel, and from this information, selects a medical device 
(e.g., a patch or graft/stent) that is optimal for the patient. 
Example methods for evaluating potential treatment options 
for a patient using a fluid-solid interaction biomechanical 
model is further described with respect to FIGS. 12 and 13. 
[0046] In some embodiments, the biomechanical model 31 
uses coupled solid and fluid mechanics equations as well as 
data stored within the database 12 in a numerical algorithm 
that employs finite difference, peri dynamic, other meshless, 
and/or finite element analysis in calculating stresses in blood 
vessel walls and blood flow parameters within an existing or 
reconstructed blood vessel. The biomechanical model 31 can 
also be used to calculate various mechanical and hemody-
namic parameters linked to restenosis, such as maximum 
stress or cyclic stress or strain, wall pressure, wall shear 
stress, oscillatory shear stress, blood viscosity, and spatial 
gradients such as wall pressure gradients and wall shear stress 
gradients. Example model inputs that can be used by the 
biomechanical model 31 to calculate these stresses comprise 
the material properties of the blood vessel (e.g., linear, non-
linear, isotropy, anisotropy, viscoelasticity), the deformation 
characteristics of the blood vessel (e.g., small versus large 
deformations), the blood flow characteristics of the blood 
vessel (e.g., laminar versus turbulent blood flows, Newtonian 
vs. non-Newtonian rheology), and the type of attachment and 
closure (e.g., closure with suture, stitching, frictional attach-
ment). 
[0047] The biomechanical model 31 can be used for pre-
dicting outputs associated with humans, animals, or both. In 
some embodiments, for example, the biomechanical model 
31 employs an animal model for evaluating and predicting 
various outputs related to vascular interventions and recon-
structions in animals such as rats, dogs, or pigs. Information 
acquired from the animal model may provide users 20, 30 
with information for researching both the underlying mecha-
nisms of diseases such as atherosclerosis as well as assisting 
in the development of improved materials, devices, and treat-
ment methods. The biomechanical model 31 can employ 
semi-destructive, destructive, or non-invasive techniques for 
evaluating animals, either in vivo or postmortem. Simulated 
results from the biomechanical model 31 can be compared to 
data obtained and stored in the database 12. As with human 
data contained within the database 12, the animal data can be 
categorized and stored for later analysis by animal type, age, 
condition, as well as other categories. 
[0048] The suite of evaluation modules 32 can be accessed 
by the system users 20, 30 to input and evaluate various 
physiologic parameters relating to current or past patients 22, 
24 as well as device-specific parameters relating to those 
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medical devices (e.g., patches, stents, grafts) that are avail-
able for treating the patients 22, 24. In the embodiment of 
FIG. 1, the suite of evaluation modules 32 includes a 
mechanical properties evaluation module 34 for inputting and 
evaluating data relating to the mechanical behavior of bio-
logical materials and medical devices such as patches, syn-
thetic grafts, and stents; a blood rheology evaluation module 
36 for inputting and evaluating data relating to the rheological 
behavior of blood, a blood vessel geometry evaluation mod-
ule 38 for inputting and evaluation data relating to the geom-
etry of a diseased or reconstructed blood vessel; a medical 
device geometry evaluation module 40 for inputting and 
evaluating data relating to medical device geometry; a bound-
ary blood flow evaluation module 42 for inputting and evalu-
ating data relating to blood flow properties, and a load evalu-
ation module 44 for inputting and evaluating data relating to 
loads on the blood vessels. In some embodiments, each indi-
vidual module 34, 36, 38, 40, 42, 44 includes an associated 
module database 46, 48, 50, 52, 54, 56 for storing module-
specific data for later analysis and use. In certain embodi-
ments' the module databases 46, 48, 50, 52, 54, 56 are a part 
of the database 12. In other embodiments, the module data-
bases 46, 48, 50, 52, 54, 56 are separate databases that interact 
with the database 12. 
[0049] The mechanical properties evaluation module 34 is 
configured for use in inputting and evaluating various input 
parameters 58 relating to the mechanical behavior ofbiologi-
cal materials and specimens such as blood vessels and plaque 
as well as the behavior of natural and synthetic grafts and 
stents used for treating such vessels. The data inputted to the 
mechanical properties input module 34 can be classified 
within the database 46 into appropriate groups, depending on 
the particular blood vessel under evaluation, the particular 
treatment method performed (e.g., endarterectomy with a 
natural graft), as well as other classifications. Example data 
that can be classified within the database 46 comprise the type 
of artery, patient age, disease type, disease stage, plaque 
extent, plaque composition, and natural graft source. Several 
example input parameters 58 that can be input to the database 
46 for use in analyzing blood vessels, plaques, and natural 
grafts are further described with respect to FIG. 2. 
[0050] For the analysis of the mechanical behavior of syn-
thetic grafts and stents, the data can be similarly classified 
into appropriate groups within the database 46 for later analy-
sis by the mechanical properties evaluation module 34. 
Example data that can be classified within the database 46 
comprise the type of material and coating, if any, the device 
manufacturer, U.S. Federal and Drug Administration (FDA) 
approval status, the frequency of use, and the percentage of 
known complications. Several example input parameters 60 
that can be input to the database 46 for use by the mechanical 
properties evaluation module 34 in analyzing synthetic grafts 
are further described with respect to FIG. 3. Several example 
input parameters 62 that can be input to the database 46 for 
use by module 34 in analyzing stents are further described 
with respect to FIG. 4. 
[0051] Different types of synthetic and natural grafts, 
stents, and other implantable devices can be evaluated using 
the mechanical properties evaluation module 34, including 
those commonly used for vascular repair, bypass, replace-
ment, and post endarterectomy patching. Example graft types 
that can be evaluated comprise polytetrafluoroethylene 
(PTFE) and other biocompatible polymer grafts, textile 
Dacron grafts, biodegradable polymer grafts, vascular grafts, 
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femoral vein/artery, aortoiliac artery, saphenous, external 
jugular and facial vein vascular grafts and allografts, bovine 
pericardium patches, tubular vascular conduits and prosthe-
ses, and v-shaped grafts. Example stent types that can be 
evaluated comprise shape memory alloys and steel stents, 
open cell and closed cell stents, self expanding stents, shape 
memory alloy stents, braided mesh stents, biodegradable 
stents, coated stents, and drug eluting stents. 
[0052] The blood rheology evaluation module 36 is config-
ured for use in inputting and evaluating various parameters 64 
relating to the rheological behavior of blood. The data input-
ted to the blood rheology evaluation module 36 can be clas-
sified within database 48 into appropriate groups for later 
analysis by the module 36. Example data that can be classified 
within the database 48 comprise blood composition param-
eters such as erythrocytes count and LDLlHDL cholesterol 
content, patient condition, and blood disease. Several input 
parameters 64 that can be input to the database 48 for use in 
analyzing rheological behavior of blood are further described 
with respect to FIG. 5. 
[0053] The blood vessel geometry input module 38 is con-
figured for use in inputting and evaluating various input 
parameters 66 related to the geometry of a blood vessel being 
treated, or for bypass-type procedures involving diseased 
blood vessels, for evaluating input parameters 66 related to 
reconstructed vessels. The data inputted to the blood vessel 
geometry evaluation module 38 can be classified within the 
database 50 for later analysis by the biomechanical model 31. 
Example data that can be classified within the database 50 
comprise vessel type, patient condition, disease type, and 
disease stage. Several example input parameters 66 that can 
be input to the database 50 for use in analyzing blood vessel 
geometry are further described with respect to FIG. 6. 
[0054] The medical device geometry input module 40 is 
configured for use in inputting and evaluating various input 
parameters 68 related to the geometrical properties (e.g., size, 
shape, curvature, etc.) of a graft or stent. The data inputted to 
the module 40 can be classified within the database 52 into 
appropriate groups for later analysis by the biomechanical 
model 31. Example data that can be classified within the 
database 52 comprise device type, manufacturer type, FDA 
approval status, frequency of use, and type and percentage of 
known complications. Several input parameters 68 that can be 
input to the database 52 for use in analyzing graft! stent geom-
etry are further described with respect to FIG. 7. 
[0055] The boundary blood flow evaluation module 42 is 
configured for use in inputting and evaluating various input 
parameters 70 related to the flow of blood and blood pressure 
at the boundaries of a region under evaluation, such as, for 
example, at the boundaries of a diseased portion of a blood 
vessel to be treated or a reconstructed vessel. The data input-
ted to the boundary blood flow evaluation module 42 can be 
classified within the database 54 for later analysis by the 
module 42. Example data that can be classified within the 
database 54 comprise vessel type, arterial geometry charac-
teristics, flow profile, pressure waveform, patient condition, 
patient activity, blood type, and reconstruction type. Several 
example input parameters 70 that can be input to the database 
54 for use in analyzing blood flow parameters are further 
described with respect to FIG. 8. 
[0056] The load evaluation module 44 is configured for use 
in inputting and evaluating various input parameters 72 
related to dynamic and static loads exerted on a blood vessel 
or other anatomical structure resulting from blood pressure, 
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body movements, adjacent tissue, forces from expanded 
stents/grafts, extension/contractions due to movement and 
residual stresses, as well as other factors. The data inputted to 
the load evaluation module 44 can be classified within the 
database 56 for later analysis by the load evaluation module 
44. Example data that can be classified within the database 56 
comprise vessel type, arterial geometry characteristics, flow 
profile, patient condition, patient activity, and device or 
reconstruction type. Several example input parameters 72 
that can be input to the database 56 for use in analyzing 
dynamic and static loads are further described with respect to 
FIG. 9. 
[0057] The evaluation unit 14 is configured to directly com-
pute biomechanics data outputs 73 for analysis by the users 
20,30. Examples of biomechanics data outputs 73 comprise 
time-dependent, three-dimensional distributions of stresses 
within a vessel wall, time-dependent; three-dimensional dis-
tributions of blood velocities, pressure, and shear stresses in 
blood; medical device material; and medical device geom-
etry. The evaluation unit 14 can also be used to compute one 
or more derivative parameter outputs 74 associated with the 
biomechanics data. Example derivative parameter outputs 74 
comprise atherosclerosis-related parameters including cyclic 
stress, cyclic strain, wall shear stress and their maximal 
minima, areas/volumes over threshold(s), prediction of 
potential restenosis locations/volumes, and prediction of 
mechanical failures. The derivative parameter outputs 74 can 
comprise quantitative values, qualitative data, or a combina-
tion of both. In some embodiments, the derivative parameter 
outputs 74 are computed using additional modules such as a 
restenosis prediction module 76 or a failure prediction mod-
ule 84, which contain additional models and model inputs. 
[0058] The restenosis prediction module 76 can be used for 
predicting the likelihood that restenosis will occur within a 
particular blood vessel. In certain embodiments, for example, 
the restenosis prediction module 76 includes functionality 
that links computed parameters such as vessel wall stresses 
and blood flow parameters to tissue remodeling and resteno-
sis using an appropriate atherogenesis theory, which 
describes growth of atheromas or plaques in the inner lining 
of arteries. Alternatively, or in addition, the restenosis predic-
tion module 76 includes functionality that links parameters 
such as vessel wall stresses and strains and blood flow char-
acteristics to tissue using a hemorheologic-hemodynamic 
theory of atherosclerosis. An example of such prediction for 
a carotid artery is shown in FIGS. lOa-lOb, which shows 
posterior and anterior three-dimensional visualizations of 
carotid artery stresses. 
[0059] In some embodiments, the restenosis prediction 
module 76 comprises a model that links computed mechani-
cal and hemodynamic parameters to atherogenesis. Various 
physiological and biochemical phenomena accompanying 
restenosis can also be incorporated into the restenosis predic-
tion module 76. For example, the restenosis prediction mod-
ule 76 can model mechanotransduction and the effects of 
mechanical stimuli on migration of endothelial cells (e.g. via 
the wound-healing model), the effects of stresses and high 
uniaxiallbiaxial strains on SMC signaling, alignment, or apo-
ptosis, various biochemical processes triggered by stress and 
strain induced gene expressions, as well as other physiologi-
cal and biochemical phenomena. The restenosis prediction 
module 76 can also be used to evaluate the effects of resteno-
sis-suppressing drugs eluted from drug-eluting stents or 
grafts. In addition, the restenosis prediction module 76 can 
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also be used to evaluate various patient-specific factors 
known to affect atherogenesis such as, for example, morpho-
logical, genetic, metabolic, and hormonal factors as well as 
relevant diseases such as hypertension. In some embodi-
ments, the restenosis prediction module 76 is configured to 
perform blood vessel remodeling to predict the development 
of stenotic-induced aneurysms resulting from a stenosis. 
[0060] In certain embodiments, the restenosis prediction 
module 76 is configured to generate three-dimensional 
images of predicted restenosis localization and growth that 
can be compared with actual atherosclerosis localization 
using direct postmortem observations or a suitable imaging 
technique such as high-resolution CT, MRI, or ultrasound 
imaging. An example imaging technique for visualizing ath-
erosclerosis localization includes hybrid PET-CT or PET-
MRI imaging with appropriate biochemical atherogenesis 
markers. In some embodiments, and as further discussed 
herein, the restenosis prediction module 76 can be used in 
conjunction with an optimization evaluation module 78 to 
define various restenosis-related criteria and goals. 
[0061] The treatment selection/optimization evaluation 
module 78 is configured for use in evaluating a range of 
available treatment options and for selecting a treatment that 
is best suited for a particular patient. Example treatment 
parameters that can be optimized via the module 78 comprise 
the type of treatment, the type of stent/graft material, the base 
geometry of the stent/graft, placement location, and attach-
ment location/configuration. In use, the treatment selection/ 
optimization evaluation module 78 employs a mathematical 
optimization routine using linear or non-linear programming 
techniques to automatically determine an optimized treat-
ment plan based on the available data stored in the database 
12. In some embodiments, the treatment selection/optimiza-
tion evaluation module 78 continuously varies one or more 
discretionary variables based on user input preferences. For 
example, one or more surgeon-defined variables can be used 
as inputs by the treatment selection/optimization evaluation 
module 78 to determine an optimized treatment option that 
takes into account the surgeon's experience and preferences. 
Example discretionary variables that can be inputted com-
prise patch or stent size, type and shape preferences, place-
ment location, and attachment location. An example of such 
an evaluation for a carotid artery repaired with different sur-
gical reconstruction techniques is shown in FIGS. 17a-17e, in 
which "PC" represents a primary closure, "CEE" represents 
eversion endarterectomy, "LPAT" represents lateral patching, 
"APAT8" represents anterior patching with a standard 8 mm 
patch, "APAT16" represents anterior patching with a wide 16 
mm patch, and "APAT4" represents anterior patching with a 
narrow 4 mm patch. 
[0062] In some embodiments, the optimization of a particu-
lar treatment option can be performed by the treatment selec-
tion/optimization evaluation module 78 by visually evaluat-
ing the output from a graphical user interface (GUI) 90. 
Furthermore, and in some embodiments, the treatment selec-
tion/optimization evaluation module 78 can also be used to 
quantitatively compare outputs from several possible treat-
ment options based on appropriate selection criteria. The 
selection criteria can be based, for example, on absolute 
maximum or cycle stress or strain intensities in the vessel 
walls, relative (e.g., percentage) increases in such intensities, 
comparisons of the vessel before repair to a healthy vessel, 
blood flow velocity (e.g., stagnation points), and wall shear 
stress. Other inputs from one or more of the evaluation mod-
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ules 32 can also be used as selection criteria for optimizing a 
particular treatment. An example visualization showing flow 
abnormalities in a carotid bulb during systole and diastole is 
shown in FIGS. 19a and 19b, respectively. 
[0063] In some embodiments, the treatment selection opti-
mization evaluation module 78 is configured to screen and 
rank specific user-selected treatment options for evaluation. 
Example options that can be screened and ranked comprise 
the type of treatment (e.g., angioplasty with or without stent-
ing, endarterectomy followed by primary closure, eversion 
endarterectomy, endarterectomy followed by primary clo-
sure, and eversion endarterectomy with lateral or anterior 
patch closure), graft material (e.g., synthetic, biological, by 
comparison/ranking of FDA-approved patches), the graft or 
stent geometry (e.g., shape, size, diameter, length, open cell, 
closed cell), the graft or stent placement (e.g., implantation 
position, overlaps), and attachment/bonding to the vessel 
(e.g., stitching, self-expanded, balloon-expanded). Examples 
of such treatment screening for carotid and superficial arteries 
is shown in FIGS. 20-22. 
[0064] A design evaluation module 80 is configured for use 
in evaluating material properties, device geometries, and 
other design parameters for new materials or device designs. 
The design evaluation module 80 can be used, for example, by 
medical device developers or material developers in develop-
ing new materials or device geometries for improving, and in 
some case optimizing, treatment outcomes. In the context of 
endarterectomy procedures, for example, the design evalua-
tion module 80 can be utilized as a guide for medical device 
developers to develop new materials and geometries for 
implantable devices such as grafts and stents. Various user-
specified ranges of allowable material properties and device 
parameter combinations can be examined by the design 
evaluation module 80, either manually, semi-automatically, 
or automatically. The design evaluation module 80 can utilize 
mean anatomic, physiological, and other patient-related data 
computing using the database entries for multiple patients 
such as, for example, patients belonging to a specific group. 
When computed for specific groups, the module outcomes 
will be related to that group. In other embodiments, the design 
evaluation module 80 can be used in conjunction with indi-
vidual patient inputs, thus designing the materials and/or 
devices for that specific patient. 
[0065] In some embodiments, the design evaluation mod-
ule 80 uses pre-characterized design moduli stored within the 
database 12 for developing new materials and/or devices. In 
certain embodiments, the design moduli comprise optimiza-
tion parameters contained within the database 12 that can be 
applied to a model used by the design evaluation module 80 to 
achieve a particular goal. For example, in developing new 
materials for synthetic grafts, the design evaluation module 
80 can employ various micromechanics models ofheteroge-
neous porous or composite synthetic graft materials to select 
an appropriate composition and structure to achieve a desired 
property such as anisotropy ratio, certain types of non-linear-
ity, strength, fatigue resistance, or biocompatibility. In similar 
fashion, stent geometry and composition can be adjusted to 
achieve certain goals. In some embodiments, the design 
evaluation module 80 also uses individual patient measure-
ments for individualizing the design and manufacturing of 
materials and/or structures to the patient's particular needs. 
[0066] In some embodiments, the output results from the 
design evaluation module 80 can be fed to a programmable 
manufacturing device 82 capable of automatically producing 
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the new material or device based on the optimized material or 
structure. Example manufacturing devices 82 capable of 
automatically producing new materials or devices comprise 
automatic programmable devices for producing porous mate-
rials, automated programmable lay-up devices for producing 
composite materials, and automated laser cutting devices for 
programmable stent manufacturing. 
[0067] A failure prediction module 84 is configured for use 
in evaluating potential failures associated with graft materi-
als, stents, or other implantable devices. In addition to rest-
enosis, implantable devices such as grafts and stents can also 
fail mechanically under long-term cyclic loading, typically 
through the gradual accumulation and propagation of cracks 
or other irregularities in the structure. In some cases, the 
mechanical failure of the device can lead to immediate artery 
blockage or thrombosis. Such mechanical failures can also 
lead to high wall stresses, abnormal flow shear stress and 
disturbed blood flow patterns at the location of the failure, 
which can result in a rapidly accelerated restenosis or other 
complications. The failure of implantable devices such as 
grafts and stents thus represents a specific modality of pos-
sible post vascular surgery complications which, in addition 
to restenosis, can affect long-term treatment outcomes. 
Examples of zones prone to potential failure of a repair device 
used to repair carotid and superficial arteries are shown in 
FIGS. 19-20. 
[0068] In some embodiments, the failure prediction mod-
ule 84 applies measured input parameters to a failure predic-
tion model that uses a combination of static and fatigue 
strength, damage, and fracture mechanics approaches typi-
cally employed for analyzing structural materials. Based on 
the measured input parameters, the failure prediction module 
84 is configured to predict and track gradual failure progres-
sion in grafts and stents. The failure prediction module 84 also 
considers the effects of changes in the material properties of 
the graft or stent during fatigue degradation along with the 
associated changes in wall stresses and blood flow patterns 
along with the effects of restenosis. In some embodiments, 
the evaluated and predicted cyclic graft or stent durability can 
be used as a goal or criteria for designing improved grafts or 
stents that are less likely to fail or cause restenosis. 
[0069] Other modules can also be utilized for evaluating 
other physiological parameters associated with a patient 22, 
24 or group of patients 22, 24, for evaluating material or 
structural parameters for devices to be used for treating 
patients 22, 24, or for performing other tasks. In addition, data 
acquired from one or more of the modules 32 can be analyzed 
by one or more other modules to evaluate, and in some cases 
predict, other parameters. Although each of the modules 32 
are described functionally as separate modules, in other 
embodiments one or more of the modules can be combined 
together into a single module or groups of modules. Further-
more, one or more of the modules 32 can comprise an external 
module that is physically embodied on another computing 
device or multiple devices. 
[0070] In those embodiments in which the system is acces-
sible to multiple users 20, 30 (e.g., as a software program 
operable over a network server or as a stand-alone software 
program), the number and type of modules made available to 
the users 20, 30 may vary depending on the user type. Thus, 
while several example modules 32 are shown in FIG. 1, the 
particular configuration of the system 10, including the types 
and functionality of modules 32 available to a particular user 
20,30, may vary depending on the particular application. For 
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health care professions, for example, the functionality pro-
vided by the modules 32 include features that assist in input-
ting potential treatment options for patients whereas the func-
tionality provided by the modules 32 for researchers are 
focused on research-related functionality. 
[0071] The system users 20, 30 can interact with the data-
base 12 and other system components either directly or via the 
network interface 26. In some embodiments, an interactive 
graphical user interface (GUI) 90 can be used by the users 20, 
30 for analyzing data generated by the biomechanical model 
31 andlor the various modules 32. In certain embodiments, 
for example, the graphical user interface 90 can be used by 
surgeons and health care professionals for preoperative 
analysis, evaluation, and visualization of treatment outcomes 
for individual patients or groups of patients, or for optimizing 
potential treatment options. For example, the graphical user 
interface 90 can be used by surgeons in endarterectomy pro-
cedures for manipulating surgical outputs such as graft/stent 
size and placement location based on various physiological 
parameters assessed visually using MRA, CTA, or other suit-
able visualization technique, and based on patient ECG data. 
[0072] The graphical user interface 90 includes database 
tools 91 for use in performing various database operations, 
model assembly tools 92 for use in generating models, simu-
lation control tools 93 for use in performing biomechanics 
modeling and simulation operations, output analysis and 
visualization tools 94 for performing analyses on outputs 
generated by the evaluation unit 14, and optimization control 
tools 95 for use in optimizing outputs generated by the evalu-
ation unit 14. 
[0073] Example database operations that can be performed 
via the database tools 91 comprise importing data into the 
database 12 as well as formatting, reducing, labeling, storing, 
andlorperforming other operations associated with such data. 
The database tools 91 can also include a search query module 
that can be used for searching the database 12. In certain 
embodiments, for example, the search query module com-
prises a search bar or interactive interface displayed on the 
graphical user interface 90, allowing the users 20, 30 to search 
for data in the database 12 by inputting a text query or by 
answering a series of questions. 
[0074] Example biomechanics operations that can be per-
formed via the model assembly tools 92 comprise inputting 
patient data directly to the biomechanical model 31, selecting 
additional data from the database 12 (e.g., via searching, 
comparing, selecting functions), assembling three-dimen-
sional blood vessel models, and running biometric simula-
tions. 
[0075] Example visualizations that can be provided via the 
simulation control tools 93 comprise three-dimensional 
graphs with areas or volumes that are color or gray-level 
coded to indicate stress, strain, and velocity intensities, vector 
plots for indicating intensity and direction, three-dimensional 
geometry of regrown tissue due to remodeling, animation 
videos showing deformation and stress/velocity changes over 
time during cyclic or other dynamic loading or as a result of 
biodegradation or other long-term phenomena in vessels or 
grafts/stents, sectioning for still-graphs, and animated videos 
for representing complex three-dimensional distributions of 
parameters. The sectioning of items on the graphical user 
interface 90 can be pre-determined or made adjustable based 
on user input. An example three dimensional visualization of 
the stresses within a blood vessel is shown in FIG. 10. 
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[0076] Example analyses and/or optimization operations 
that can be performed via the output analysis and visualiza-
tion tools 94 and the optimization control tools 95 comprise 
computing derivative output parameters on biomechanics 
data outputs, visualizing anatomical structures for evaluation 
or comparison (e.g., via mapping color-coded parameters 
over pulsating blood vessel surface and/or section of a ves-
sel), for performing side-by-side visual comparisons of mul-
tiple treatment options under consideration, for computing 
maxima/minima and/or areas/volumes over a threshold for 
quantitative comparison of multiple treatment options, for 
performing automatic or semi-automatic optimizations (e.g., 
using computational loops and/or non-linear programming 
methods), and for storing or exporting optimal treatment 
techniques, materials, devices, and adjustable parameters for 
further use by surgeons, materials developers, or medical 
device manufacturers. 
[0077] In some embodiments, the graphical user interface 
90 can be utilized for performing postoperative evaluations to 
assess the quality and patency of a completed therapy, or to 
evaluate possible reasons for detected or diagnosed anoma-
lies or other complications. For complications such as rest-
enosis, for example, the graphical user interface 90 can be 
used to perform research on the underlying cause or causes of 
the restenosis, and in some cases, can be used to individualize 
patient care. In some embodiments, the graphical user inter-
face 90 can be used for performing real-time evaluations of a 
selected treatment option during an interventional procedure 
based on either real-time, intraoperative measurements 
obtained from the patient or based on a combination of real-
time and preoperative measurements stored within the data-
base 12. The ability to analyze and predict outcomes based on 
such data may be of particular interest in the case of an 
emergency or when intraoperative complications may arise 
with little or no preparatory time. 
[0078] The graphical user interface 90 can be used to quan-
titatively and/or qualitatively evaluate certain conditions 
based on appropriate selected criteria. The selection criteria 
can be based, for example, on absolute maximum or temporal 
mean or cyclic values of stress and/or strain intensities in the 
vessel walls, relative (e.g., percentage) increases in such 
intensities compared to the vessel before repair or to a healthy 
vessel, blood flow velocity characteristics (e.g., stagnation 
points), and wall shear stress. The processor 18 is configured 
to find critical spots, calculate their extent, and color-code 
them onto three-dimensional visualization outputs, such as 
graphs and videos, that can be displayed on the graphical user 
interface 90 for analysis. The users 20, can select between one 
or multiple, pre-programmed, interactively adjustable thresh-
old levels, and perform other tasks via the graphical user 
interface 90. Three-dimensional geometric information 
obtained via an imaging system can be combined as a com-
posite image on the graphical user interface 90 along with the 
localization of targeted biochemical events identified by 
markers. The resultant, calculated three-dimensional images 
containing marked critical locations can then be directly com-
pared with restenosis occurring in treated patients 24 for 
further analysis. 
[0079] FIG. 2 is a schematic view showing several example 
input parameters 58 for use by the mechanical properties 
evaluation module 34 of FIG. 1 in analyzing the behavior of 
biological materials and anatomical structures such as blood 
vessels, plaques, and natural grafts. As shown in FIG. 2, the 
mechanical properties evaluation module 34 receives, as 
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input parameters 58, a specimen type/geometry input param-
eter 98, a load type, rate, and sequence input parameter 100, 
an isotropy/anisotropy input parameter 102, a linear/non-
linear input parameter 104, a constitutive equations input 
parameter 105, and a material homogeneity input parameter 
106. The specimen type input parameter 98 relates to the type 
of blood vessel to be evaluated. For example, if the specimen 
to be evaluated is a natural graft, the specimen type input 
parameter 98 can be used to select the type and source of the 
graft (e.g., natural graft: saphenous or external jugular vein) 
and its geometry. If the specimen to be evaluated is plaque, the 
specimen type input parameter 98 can be used to input data 
relating to the extent and composition of the plaque. 
[0080] The load type input, rate and sequence parameter 
100 relates to the loading conditions (e.g., uniaxial or biaxial, 
rate, sequence) in which blood vessel or graft measurements 
were acquired. The isotropy/anisotropy input parameter 102 
relates to whether the blood vessel or graft is to be approxi-
mated by the biomechanical model 31 as either isotropic or 
anisotropic. The linear-/non-linear input parameter 104, 
relates to whether the blood vessel or graft is to be approxi-
mated by the biomechanical model 31 as either linear or 
non-linear (e.g., hyperelastic), elastic, or viscoelastic. The 
constitutive equations input parameter 105 relates to the 
equations to be used by the module 34 in evaluating outputs. 
The material homogeneity input parameter 106 relates to 
whether the blood vessel or graft is to be modeled as a homog-
enous or heterogeneous material. For a heterogeneous mate-
rial, the mechanical behavior can be approximated by a com-
posite mechanical model that uses the measured behavior of 
multiple components or constituents. For example, blood ves-
sel walls can be considered as a layered, heterogeneous struc-
ture consisting of the intima, media, and adventitia, each with 
distinct, measurable properties. Plaque, in turn, can be con-
sidered as a heterogeneous structure consisting of dense, rela-
tively acellular fibrous tissue, calcified tissue, pultaceous 
debris (i.e., amorphous debris containing cholesterol clefts 
rich in extracellular lipid), and cellular fibrous tissue. 
[0081] The mechanical properties evaluation module 34 
can be further configured to receive one or more other mea-
sured or modeled input parameters 108 for analysis. 
Examples of other parameters 108 that can be input to the 
mechanical properties evaluation module 34 comprise 
chemical, mechanical, or electrical characteristics of the 
structure to be evaluated, data input to other evaluation mod-
ules, as well as the outputs generated by other evaluation 
modules. 
[0082] Based on the input parameters 58, experiments, con-
stitutive fittings, and other factors are used by the mechanical 
properties evaluation module 34 to generate one or more 
outputs 110 associated with the condition of the blood vessel, 
plaque or graft. Examples of outputs 11 0 that can be evaluated 
comprise raw data 110a such as stress/strains and constitutive 
parameters 11 Ob that describe blood, arterial wall, plaque and 
repair material or device behavior, tissue growth and remod-
eling conditions. 
[0083] FIG. 3 is a schematic view showing several example 
input parameters 60 for use by the mechanical properties 
evaluation module 34 in analyzing the behavior of synthetic 
grafts. As shown in FIG. 3, the mechanical properties evalu-
ation module 34 receives, as input parameters 60, a synthetic 
graft type and geometry input parameter 112, a load type, 
rate, and sequence input parameter 114, an isotropy/anisot-
ropy input parameter 116, a linear/non -linear input parameter 
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118, a constitutive equations input parameter 119, a material 
homogeneity input parameter 120, and a time-dependent 
behavior/failure input parameter 122. 
[0084] The graft mechanical properties can be either evalu-
ated experimentally or by modeling. For synthetic grafts such 
as polytetrafluoroethylene (PTFE) grafts, the material can be 
modeled as a porous material whose behavior is approxi-
mated based on the behavior ofPTFE and the volume fraction 
and shape of the pores. For textile grafts, the behavior can be 
predicted based on the fiber properties and textile structure. 
For biodegradable polymeric grafts, the mechanical proper-
ties evaluation module 34 is further configured to receive a 
time-dependent behavior/failure input parameter 122 that 
takes into account the degradation characteristics of the graft 
over time. One or more other measured or modeled input 
parameters 124 can also be received for analysis by the 
mechanical properties evaluation module 34. 
[0085] Based on the input parameters 60, experiments, con-
stitutive fittings, failure model fittings, and other factors are 
used by the mechanical properties evaluation module 34 to 
generate one or more outputs 126 associated with the syn-
thetic graft. Examples of outputs 126 that can be evaluated 
comprise raw data 126a, constitutive parameters 126b (e.g., 
tissue remodeling laws that describe the tissue growth within 
and around the graft), and failure model parameters 126c 
(e.g., time-dependent change of graft material properties). 
[0086] FIG. 4 is a schematic view showing several example 
input parameters 62 for use by the mechanical properties 
evaluation module 34 in analyzing the behavior of stents. As 
shown in FIG. 4, the module 34 receives, as input parameters 
62, a stent type and geometry input parameter 128, a load type 
input parameter 130, a material properties input parameter 
131, an isotropy/anisotropy input parameter 132, a linear/ 
non-linear input parameter 134, a constitutive equations input 
parameter 135, and a material homogeneity input parameter 
136. The stent type and geometry input parameter 128 can be 
used to select the type and geometry of the stent to be ana-
lyzed. For example, the stent type input and geometry param-
eter 128 can be used to select between evaluating a quasi-
homogenous solid shell stent or a wire-mesh type stent. In the 
context of homogenous type stents, the load type and rate 
input parameter 130 relates to whether the stent is to be 
modeled as axially loaded under tension or compression (i.e., 
uniaxial loading), or simultaneous radial expansion, axial 
tension/compression and torsion (i.e., biaxial loading includ-
ing the effects of shear). 
[0087] For biodegradable polymeric stents, the module 34 
is further configured to receive a time-dependent failure/be-
havior input parameter 138 that is used for evaluating the 
degradation characteristics of the stent over time. For stents 
made from shape-memory alloys, the temperature and strain-
dependent behavior of the alloy can be provided as an input 
parameter 140 to the mechanical properties evaluation mod-
ule 34, either as a measured value or approximated based on 
modeling. One or more other measured or modeled input 
parameters 142 can also be received for analysis by the 
mechanical behavior evaluation module 34. 
[0088] Based on the input parameters 62, experiments, con-
stitutive fittings, failure model fittings, and other factors are 
used by the mechanical behavior evaluation module 34 to 
generate one or more outputs 144 associated with the stent. 
Examples of outputs 144 that can be evaluated comprise raw 
data 144a, constitutive parameters 144b (e.g., tissue growth 
laws within the stent, degree of inflammation), and failure 
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model parameters 144c (e.g., number and severity of devel-
oped cracks, stent migration, and alteration of stent and adja-
cent wall geometry). 
[0089] FIG. 5 is a schematic view showing several example 
input parameters 64 for use by the blood rheology evaluation 
module 36 of FIG. 1 in analyzing rheological behavior of 
blood. As shown in FIG. 5, the blood rheology evaluation 
module 36 receives, as input parameters 64, a blood type and 
composition input parameter 146, a load type and rate input 
parameter 148, a linear/non-linear input parameter 150, a 
rheologic constitutive equation input parameter 151, and a 
blood disease input parameter 152. The blood type and com-
position input parameter 146 relates to the specific blood type 
and composition of the patient's blood, and includes factors 
such as erythrocytes count and LDLlHDL cholesterol con-
tent. The load type and rate input parameter 148 relates to the 
loading conditions of blood. The linear/non-linear input 
parameter 150 relates to whether the blood is to be approxi-
mated by the blood evaluation module 36 as either a Newto-
nian or non-Newtonian fluid for purposes of modeling. The 
rheoologic constitutive equation input parameter 151 relates 
to the rheologic equations to be used for modeling. The blood 
disease input parameter 152 relates to whether the patient has 
a particular blood-related disease or disorder, and if so, pro-
vides specific information related to that disease or disorder 
such as the disease stage. If, for example, the patient has 
Leukemia, the blood disease input parameter 152 can be used 
to input the type of Leukemia (i.e., lymphocytic or myelog-
enous) and the severity of the disorder (i.e., acute or chronic). 
One or more other measured or modeled input parameters 
154 can also be received for analysis by the blood rheology 
evaluation module 36. 
[0090] Based on the input parameters 64, experiments, con-
stitutive fittings, and other factors are used by the blood 
evaluation module 36 to generate one or more outputs 155 
associated with the patient's blood. Examples of outputs 155 
that can be evaluated comprise raw data 155a such as blood 
viscosity, shape and size of erythrocytes and constitutive 
parameters 155b such as laws to describe the viscous prop-
erties of blood. 
[0091] FIG. 6 is a schematic view showing several example 
input parameters 66 for use by the blood vessel geometry 
evaluation module 38 of FIG. 1 in analyzing the geometry of 
blood vessels or reconstructed blood vessels. As shown in 
FIG. 6, the blood vessel geometry evaluation module 38 
receives, as input parameters 66, a blood vessel type, seg-
ment, and location input parameter 156, a blood vessel 
dimensions and branches input parameter 158, and a disease 
type input parameter 160. The blood vessel type, segment, 
and location input parameter 156 relates to the type and 
location of the blood vessel to be treated. For reconstructed 
blood vessels using harvested vessels, the blood vessel type, 
segment, and location input parameter 156 relates to the type 
and location of the harvested vessel. The blood vessel dimen-
sions and branches input parameter 158 relates to the dimen-
sions and branches of the vessel being treated, or for vessel 
reconstructions, the dimensions of the vessel to be recon-
structed. The disease type input parameter 160 relates to 
whether the patient has a particular blood vessel disease or 
disorder, and if so, provides specific information related to 
that disease or disorder such as the disease stage. If, for 
example, the patient has atherosclerosis, the disease type 
input parameter 160 can be used to input the type and the 
severity of the disease to the module 38. One or more other 
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measured or modeled input parameters 162 can also be 
received for analysis by the blood vessel geometry evaluation 
module 38. 
[0092] Based on the input parameters 62, experiments, 
medical imaging, border identification, and other factors are 
used by the blood vessel geometry evaluation module 38 to 
generate one or more outputs 164 associated with vessel 
geometry. Examples of outputs 164 that can be evaluated 
comprise raw data 164a and interpolated/reconstructed data 
164b (e.g., arterial tortuosity, curvatures, branching angles, 
variable wall thickness, length of segment under consider-
ation, three-dimensional shape). 
[0093] FIG. 7 is a schematic view showing several example 
input parameters 68 for use by the medical device geometry 
evaluation module 38 in analyzing the geometry of a medical 
device such as a graft or stent.As shown in FIG. 7, the medical 
device geometry evaluation module 40 receives, as input 
parameters 68, a graft/stent type input parameter 166 and a 
graft/stent dimensions input parameter 168. The graft/stent 
type input parameter 166 relates to the type and/or manufac-
turer of the device. The graft/stent dimensions input param-
eter 154 relates to the specific graft/stent length, the size or 
shape of a patch, or any other user-selectable geometric 
parameter. In some embodiments, the dimensions for various 
devices can be stored in the database 12, or can be varied by 
the clinician. One or more other measured or modeled input 
parameters 170 can also be received for analysis by the medi-
cal device geometry evaluation module 38. 
[0094] Based on the input parameters 64, three-dimen-
sional imaging data/reconstructions and other factors are 
used by the medical device geometry evaluation module 38 to 
generate one or more outputs 172 associated with the graft or 
stent geometry. Examples of outputs 172 that can be evalu-
ated comprise raw data 172a and three-dimensional interpo-
lated data 172b. 
[0095] FIG. 8 is a schematic view showing several example 
input parameters 70 for use by the boundary blood flow 
evaluation module 42 of FIG. 1 in analyzing blood flow. As 
shown in FIG. 8, the boundary blood flow evaluation module 
42 receives, as input parameters 70, a blood vessel type, 
geometry, and section location input parameter 174, a patient 
activity input parameter 176, a patient condition input param-
eter 178, a blood pressure input value 180, a symmetric/ 
asymmetric input value 181, and a blood type input parameter 
182. The blood vessel type, geometry, and section location 
input parameter 174 relates to the type and location of the 
blood vessel to be treated. The patient activity input param-
eter 176 relates to the general activity level of the patient, such 
as "active," or "sedentary." The patient condition input 
parameter 178 relates to the general condition of the patient. 
In some embodiments, for example, the patient condition 
input parameter 178 relates to the patient's specific condition. 
The symmetric/asymmetric input parameter 181 relates to the 
symmetry of blood flow conditions. The blood type input 
parameter 182 relates to the specific blood type of the patient. 
One or more other measured or modeled input parameters 
184 can also be received for analysis by the boundary blood 
flow evaluation module 42. 
[0096] Based on the input parameters 70, experiments, 
interpolations, and other factors are used by the boundary 
blood flow evaluation module 42 to generate one or more 
outputs 186 associated with blood flow. Examples of outputs 
186 that can be evaluated comprises raw data 186a, dynamic 
velocity profiles 186b, (e.g., three-dimensional pulsatile 
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blood velocity profiles at various locations of an arterial tree, 
peak velocity values and their corresponding luminalloca-
tions), and dynamic pressure cycles 186c. 
[0097] FIG. 9 is a schematic view showing several example 
input parameters 72 for use by the load evaluation module 44 
of FIG. 1 in analyzing dynamic and static loads exerted on 
blood vessels, reconstructions, or other anatomical struc-
tures. As shown in FIG. 9, the load evaluation module 44 
receives, as input parameters 72, a blood pressure input 
parameter 188, a force/stress input parameter 190, a blood 
vessel type input parameter 192, a patient activity input 
parameter 194, and a patient condition input parameter 196. 
The blood pressure input parameter 188 comprises the 
patient's systolic and diastolic blood pressure during one 
heart cycle or across multiple heart cycles (e.g., an averaged 
blood pressure). The force/stress input parameter 190 relates 
to external forces applied to the vessel, including, but not 
limited to, forces from surrounding tissue, neighboring grafts 
and stents, extensions and contractions due to locomotion, 
and residual stresses. The forces can be measured and/or 
evaluated at particular times such as during a period of maxi-
mum load, at systole/diastole, or during peaks in cardiac 
activity. The forces can also be measured continuously 
through dynamic or cyclic activities. One or more other mea-
sured or modeled input parameters 198 can also be received 
for analysis by the load evaluation module 44. 
[0098] Based on the input parameters 72, measurements, 
back calculation of tractions, and other factors are used by the 
load evaluation module 44 to generate one or more outputs 
200 associated with loading. Examples of outputs 200 that 
can be evaluated comprise raw data 200a and tractions on the 
vessel surface 200b (e.g., maps of distributed loads on arterial 
walls and repair devices, boundary conditions, interactions 
with surrounding tissues). 
[0099] The various input parameters supplied to the evalu-
ation modules 32 can be measured in-vitro, in-vivo, or a 
combination of both. For example, geometry and in vivo 
mechanical properties of the patient's blood vessels and/or 
atherosclerotic plaque can be measured using invasive or 
non-invasive ultrasound, MRA, PET-CTA, or CTA while 
mechanical properties of the repair materials and devices can 
be determined using in vitro biaxial tests. 
[0100] FIG. 11 is a schematic view showing an example 
software platform 202 for use with the system 10 of FIG. 1. 
The software platform 184 may represent, for example, a 
service-orientated software architecture comprising a suite of 
software tools that can be used in a cloud-based environment 
with multiple, Web-based users 20. The software platform 
202 comprises a three distinct, distributed layers 204, 206, 
208 that provide software functionality for communicating 
with the system components and with each user 20. A data 
layer 204 provides access to the underlying data manipulation 
functionality and data repositories. In some embodiments the 
data layer comprises a biomechanical data model 210, a data-
base 212, a solver 214, and data management components 
216. 
[0101] A tool layer 206 provides a suite of software tools to 
facilitate interaction with system users 20 via an Internet 
connection. Each of the software tools are modular, allowing 
functional elements to be easily incorporated into or removed 
from the system. In the embodiment of FIG. 10, the tool layer 
206 comprises a database manipulation tool suite 218 for 
importing new data into the database 212, for performing 
queries to access data stored within the database 212, for 
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reviewing data via three-dimensional representations, 
graphs, dynamic analyses (e.g., measuring dimensions, flow 
rates) and tabulating results, for performing side-by-side 
comparisons of patient data stored within the database 212 for 
multiple patients, and for performing statistical analyses to 
correlate medical records, risk factors, as well as other pre-
determined or user-definable criteria. 
[0102] A model assembly tool suite 220 provides a suite of 
software tools for building and refining biomechanics models 
for modeling medical procedures such as cardiovascular 
interventions or reconstructions. In some embodiments, the 
model assembly tool suite 220 provides functionality for 
selecting model inputs based on information within the data-
base 212 and/or based on user imported data, for assembling 
graphical interaction models (e.g., a graphical model for 
selecting between different repair techniques based on three-
dimensional vessel geometry), for automating the input of 
device types, materials, mechanical properties, rheological 
blood properties, flow properties, boundary conditions, and 
other input parameters from each of the evaluation modules, 
for selecting the size, location, and other characteristics of the 
device and/or the anatomy to be treated, and for performing 
finite element meshing. 
[0103] An output visualization and analysis tool suite 222 
provides a suite of software tools for visualizing and analyz-
ing data. In some embodiments, the output visualization and 
analysis tool suite 222 provides functionality for visualizing 
static and dynamic mechanical data (e.g., three-dimensional 
pulsatile vessel deformations or velocities, blood flow, den-
sity/color mapping, stress/strain), for interactively perform-
ing graphical manipulation of data (e.g., rotation, zooming, 
panning, highlighting), for computing and mapping other 
mechanical factors onto three-dimensional vessel geometry 
(e.g., by interactive sliding thresholds, computation of maxi-
mum or minimum values, visualization of volumes over 
thresholds), for performing both quantitative and qualitative 
side-by-side comparisons of different medical procedures 
and potential outcomes, and for storing selected data outputs 
in the database 212 and exporting data in a user-defined 
format for later analysis. 
[0104] An application programming interface (API) layer 
208 provides a framework for the various software tools to 
communicate and exchange information through the Internet. 
The system architecture allows the various tool suites and 
other tools to be deployed across multiple, different plat-
forms. In some embodiments, a centralized server architec-
ture is used for performing resource-demanding graphical 
rendering and analysis. For Internet-based applications, a 
Representational State Transfer (REST) protocol, Simple 
Object Access Protocol (SOAP), or other suitable Web-ser-
vices protocol 224 is used for exchanging information in the 
implementation of Web-based services. 
[0105] FIG. 12 is a flow diagram showing an example 
method 226 for analyzing treatment outcomes in vascular 
interventions and reconstructions using the system 10 of FIG. 
1. FIG. 12 may represent, for example, an example method 
for analyzing potential therapeutic outcomes in an endarter-
ectomy procedure of a carotid artery using the system 10 of 
FIG. 1. As shown in FIG. 12, the method may begin generally 
at block 228 in which the user is prompted to input patient-
specific data into the database for analysis. The patient data 
can include data obtained in-vivo from clinical measurements 
taken from the patient. The patient data can also include data 
such as the patient's age, gender, race, health condition, car-
11 
Apr. 5,2012 
diac risk factor profile, as well as other patient-specific infor-
mation. Once gathered, the patient specific data is then input 
to a database for later analysis (block 230). 
[0106] At block 232, and in some embodiments, the user 
searches the database to obtain additional data to be associ-
ated with the patient based on patient data stored within the 
database. If, for example, patient-specific data at block 230 is 
not available, the data can be interpolated or extrapolated 
from the database based on other patient records that are 
searchable and stored within the database. For example, if 
data on blood viscosity is not readily available, it can be 
extrapolated from the database using viscosity data from 
patients with similar clinical records (e.g., blood count, stage 
of disease, lifestyle, risk factors, etc.). 
[0107] The system next prompts the userto select treatment 
and/or medical device data to be associated with a proposed 
treatment option (block 234). The user then performs a search 
of the database and obtains model parameters to be associated 
with the biomechanical model (block 236). If, for example, 
the user desires to use finite element analysis to analyze the 
effects of pulsatile blood flow on an endarterectomized blood 
vessel, the user may select the model type from a display 
screen, and select from a number of finite element analysis 
options available for the modeling. An example finite element 
analysis model that can be used to evaluate endarterecto-
mized and patched arteries is described, for example, in 
"Finite Element Model of the Patched Human Cartoid" pub-
lished on Oct. 14,2009 in the Journal of Vascular Endovas-
cular Surgery, the contents of which are incorporated herein 
by reference in their entirety for all purposes. 
[0108] From this information, the system then generates a 
coupled fluid-solid interaction biomechanical model and 
instructions (block 238) to be used for analyzing the inputs 
and model data. The biomechanical model and instructions 
can be construed in both the fluid and solid domains using an 
appropriate system of equations for each. A biomechanics 
simulation can then be performed (block 240) and an analysis 
performed on the biomechanics data (block 242). Based on 
the modeling preferences supplied to the biomechanical 
model, the processor analyzes the data supplied to the data-
base from each of the evaluation modules to determine at least 
one potential treatment outcome using the biomechanical 
model. In some embodiments, the evaluation unit combines 
both measured and modeled data obtained across multiple 
modules to analyze potential treatment outcomes and to sug-
gest potential treatment options available for treating the 
patient. In some embodiments, an optimization is performed 
on the biometrics data to optimize the proposed treatment 
option (block 244). 
[0109] FIG. 13 is a flow diagram of another example 
method 248 for analyzing treatment outcomes in vascular 
interventions and reconstructions. FIG. 13 may represent, for 
example, an example implementation of the method 226 of 
FIG. 12 for analyzing potential therapeutic outcomes in an 
endarterectomy procedure using the system 10 of FIG. 1. As 
shown in FIG. 13, the method 248 may begin generally at 
block 250 in which patient-related data is acquired from one 
or more patients. In some embodiments, the process of 
acquiring patient data comprises acquiring geometry data 
associated with the vessel under evaluation (block 252), 
acquiring mechanical property data associated with the vessel 
(block 254), acquiring flow data associated with the flow 
characteristics of blood within the vessel (block 256), acquir-
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ing blood pressure data (block 258), and acquiring blood 
rheology data (260). Other physiological data can also be 
acquired from the patient. 
[011 0] The process of acquiring geometry data at block 252 
can be accomplished using MRI, eTA, invasive or non-inva-
sive ultrasonography, and/or other suitable technique. In 
some embodiments, the three-dimensional geometry of the 
vessel under evaluation can be analyzed (block 262), provid-
ing the clinician with information such as the size shape 
tortuousness, and/or other geometrical characteristi~s of th~ 
vessel. An example of mean reconstructed arterial geometry 
from data obtained from sixteen patients is shown in FIG. 16. 
[0111] The mechanical property data associated with the 
vessel can be acquired in-vitro, in-vivo, or using a combina-
tion of in-vitro and in-vivo techniques. For example, 
mechanical properties of patching materials that can be 
acquired in vitro using biaxial or tensile tests. Example of 
mechanical property data that can be acquired in-vivo com-
prises mechanical property data obtained using invasive and 
non-invasive ultrasonography and elastography. Based on 
these measurements, the mechanical properties of the vessel 
are obtained and constitutive models of the vessel are gener-
ated (block 264). 
[0112] The process of acquiring flow data associated with 
the flow characteristics within the vessel at block 256 can be 
accomplished artificially using MRI or ultrasonography and/ 
or in-vivo using MRI or invasive or non-invasive ultrasonog-
raphy. Based on these measurements, flow velocity profiles 
associated with the vessel is generated (block 266). 
[0113] The process of acquiring pressure data at block 258 
can comprise measuring blood pressure using an invasive or 
non-invasive sensor, an angiocatheter, or other suitable tech-
nique. In some embodiments, the pressure measurements can 
be correlated with electrocardiogram measurements. Based 
on the sensed pressure data, a blood pressure waveform is 
generated (block 268). 
[0114] The process of acquiring blood rheology data at 
block 260 can comprise measuring the blood composition, 
viscosity, shear rate, and/or other characteristics of the 
patient's blood. Based on these measurements, blood viscos-
ity constitute laws are generated, which describe the blood 
viscosity characteristics of the patient's blood (block 260). 
[0115] The three dimensional geometry data, mechanical 
properties and constitutive models, flow velocity profiles, 
pressure waveform data, and blood viscosity constitutive 
laws are stored within the database for further analysis by the 
evaluation unit (block 272). In some embodiments, informa-
tion regarding the medical devices and materials available for 
repairing the blood vessel as well as disease growth and vessel 
remodeling constitutive laws are also supplied to the database 
for further analysis by the evaluation unit, as indicated gen-
erally at blocks 274 and 276, respectively. 
[0116] Based on the data stored within the database the 
evaluation unit is configured to generate inputs and int~rpo­
late model parameters to be used by the biomechanical model 
for analyzing the acquired patient data (block 278). From this 
data, and guided by user interaction (block 280), the system 
assembles a fluid/solid interaction model (block 282) that can 
be used to generate a proposed solution (block 284). In some 
embodiments, for example, the proposed solution generated 
by the model comprises the determination of which of the 
available medical devices and/or repair materials are optimal 
for a particular diseased vessel or patient condition. In 
another embodiment, the proposed solution generated by the 
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model comprises the determination of a size or shape of a 
medical device (e.g., a stent) to be used in performing therapy 
on the patient. Other proposed solutions are also possible. 
[0117] In some embodiments, post-processing and/or 
results mapping can be performed to confirm the efficacy of 
the proposed treatment and/or to further optimize the treat-
ment (block 286). In certain embodiments, for example, 
results mapping can be performed over a three-dimensional 
blood vessel or two or three-dimensional sections of the ves-
sel to determine and visualize locations of maximum or mini-
mum values of particular factors, regions where factors 
exceed the set thresholds, stream/streak path lines on the 
plots, display plots of stress and strain, and/or viscosity, to 
perform queries for particular vessel zones, display dynamic 
graphs and three-dimensional plots, and generate area evolu-
tion graphs. Other post processing can also be performed on 
the data. 
[0118] If at block 286, atherosclerosis potentially exists at 
the treatment site, the system can analyze the disease progres-
sion based on atherosclerosis growth models (block 290). If 
the analysis confirms that the disease will not grow or if 
further optimization is not desired or possible, then the sys-
tem outputs a final result to the clinician (block 292). If, on the 
other hand, the disease is predicted to progress, the system 
performs additional treatment optimization (block 292). 
When the disease growth is predicted to terminate, the system 
outputs a final result (block 292) to the clinician. 
[0119] In some embodiments, the system may perform an 
optimization on one or more criteria or goals (block 294), 
which can be automatically provided as input to the genera-
tion of input and interpolation of model parameters at block 
278, or manually provided to the user. Examples of criteria or 
goals include the shape, size, type, location, and material. 
Such optimization can be performed at any time during the 
process, including at the post-processing and results mapping 
step (block 286), during visualization (block 290), and/or 
during the disease growth and remodeling step (block 292). 
The process of assembling the model, providing a proposed 
solution, and performing post-processing and results map-
ping can then be performed again based on the optimized data 
to obtain another result. 
[0120] FIG. 14 is a flow diagram showing an example 
method 300 for developing a material or device design using 
the system 10 of FIG. 1. FIG. 14 may represent, for example, 
an example method for developing a stent or synthetic graft 
using the system 10 of FIG. 1. As shown in FIG. 14, the 
method may begin generally at block 302 in which the user 
obtains patient specific data from a database containing data 
for multiple patients. The patient data can include data 
obtained in-vivo from clinical measurements taken from the 
patient. The patient specific data can also be obtained in-vitro. 
[0121] Based on the data stored in the database, the system 
next computes patient-related model inputs for all or groups 
of the patients (block 304). The system next prompts the user 
to select the treatment or surgery type and define ranges of 
allowable materials and/or device properties (block 306). 
[0122] From this information, the system then generates 
one or more biomechanical models (block 308) to be used for 
analyzing the inputs and model data. A biomechanics simu-
lation can then be performed (block 310) and an analysis 
performed on the biomechanics data (block 312). In some 
embodiments, an optimization is performed on the biometrics 
data to optimize the proposed treatment option (block 314). 
US 2012/0084064 Al 
[0123] FIG. 15 is a flow diagram showing an example 
method 320 for developing a material or device design using 
the system 10 of FIG. 1. FIG. 15 may represent, for example, 
an example method for developing a stent or synthetic graft 
for a specific patient using the system 10 of FIG. 1. As shown 
in FIG. 15, the method may begin generally at block 322 in 
which the user obtains patient specific data from a database 
containing data for multiple patients. The patient data can 
include data obtained in-vivo from clinical measurements 
taken from the patient. The patient specific data can also be 
obtained in-vitro. 
[0124] Based on the data stored in the database, the system 
next computes patient-related model inputs for all or groups 
of the patients (block 324). The system next prompts the user 
to select the treatment or surgery type and define ranges of 
allowable materials and/or device properties (block 326). 
[0125] From this information, the system then generates 
one or more biomechanical models (block 328) to be used for 
analyzing the inputs and model data. A biomechanics simu-
lation can then be performed (block 330) and an analysis 
performed on the biomechanics data (block 332). In some 
embodiments, an optimization is performed on the biometrics 
data to optimize the proposed treatment option (block 334). 
The optimization performance parameters that are obtained 
from the optimization are then used to develop the material 
and/or device structures (block 336). The materials and/or 
device structures are then used to produce the final material or 
device (block 338). 
[0126] Various modifications and additions can be made to 
the exemplary embodiments discussed without departing 
from the scope of the present invention. For example, while 
the embodiments described above refer to particular features, 
the scope of this invention also includes embodiments having 
different combinations of features and embodiments that do 
not include all of the described features. Accordingly, the 
scope of the present invention is intended to embrace all such 
alternatives, modifications, and variations as fall within the 
scope of the claims, together with all equivalents thereof. 
What is claimed is: 
1. A method for analyzing and predicting treatment out-
comes of vascular interventions and reconstructions, com-
prising: 
inputting patient specific data associated with a patient into 
a database; 
searching the database and obtaining additional data to be 
associated with the patient, wherein the additional data 
is obtained based at least in part on patient specific data 
stored within the database for one or more other patients; 
selecting at least one of a treatment parameter or medical 
device parameter to be used in association with a pro-
posed treatment option for treating the patient; 
searching the database and obtaining one or more model 
properties associated with the treatment or medical 
device parameter; 
generating a fluid-solid interaction biomechanical model 
based at least in part on the patient specific data, the 
additional data associated with the patient, and the 
model properties; 
performing a biomechanics simulation and generating bio-
mechanics data using the biomechanical model; and 
analyzing the biomechanics data. 
2. The method of claim 1, wherein the patient specific data 
for the patient comprises data selected from the group of data 
13 
Apr. 5,2012 
comprising age, gender, race, risk factor profile, clinical his-
tory, medications, blood count, diet, and lifestyle. 
3. The method of claim 1, wherein the patient specific data 
for the patient includes three-dimensional vessel geometry 
properties. 
4. The method of claim 1, wherein the patient specific data 
for the patient comprises data selected from the group of 
properties comprising vessel wall tissue mechanical proper-
ties and blood rheologic properties. 
5. The method of claim 1, wherein the patient specific data 
for the patient comprises data selected from the group of 
properties comprising dynamic blood flow properties, blood 
pressure cycles, and boundary conditions. 
6. The method of claim 1, wherein the patient specific data 
and model properties associated with the treatment or method 
are obtained using a plurality of input evaluation modules. 
7. The method of claim 6, wherein the plurality of input 
evaluation modules are selected from the group of modules 
comprising a mechanical properties evaluation module, a 
blood rheology evaluation module, a blood vessel geometry 
evaluation module, a medical device geometry evaluation 
module, a boundary blood flow evaluation module, and a load 
evaluation module. 
8. The method of claim 1, wherein the additional data to be 
associated with the patient is selected from the database of 
data for other patients based on clinical data for the patient. 
9. The method of claim 8, wherein the clinical data for the 
patient is selected from the group of data comprising patient 
age, gender, race, risk factors, clinical history, medications, 
diet, lifestyle and pregnancy. 
10. The method of claim 8, wherein the clinical informa-
tion for the patient includes laboratory or in-vivo tests on the 
patient. 
11. The method of claim 1, wherein selection of the treat-
ment parameter or medical device parameter comprises 
selecting at least one parameter from the group of parameters 
comprising a type of surgery or intervention, the type of 
medical device, the geometry of the medical device, the mate-
rial of the medical device, and the mechanical properties of 
the medical device. 
12. The method of claim 1, wherein generating the f1uid-
solid interaction biomechanical model comprises generating 
an algorithm for solving time-dependent, three-dimensional 
solid and fluid biomechanics equations with boundary con-
ditions based on the patient specific and additional data asso-
ciated with the patient and model properties associated with 
the treatment or medical device parameter. 
13. The method of claim 12, wherein generating the bio-
mechanics data comprises generating at least one output 
selected from the group of outputs comprising a time-depen-
dent, three-dimensional distributions of stresses and strains 
within a vessel wall or medical device, time-dependent, three-
dimensional distributions of blood velocities, pressure, and 
flow shear stresses in blood. 
14. The method of claim 1, further comprising analyzing 
one or more derivative parameters associated with the biome-
chanics data. 
15. The method of claim 14, wherein the one or more 
derivative parameters comprises at least one derivative 
parameter selected from the group of parameters comprising 
atherosclerosis-related parameters, restenosis prediction 
parameters, and device mechanical failure parameters. 
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16. The method of claim 14, wherein the derivative param-
eters are obtained by quantitatively and qualitatively analyz-
ing the biomechanics data. 
17. The method of claim 14, wherein the derivative param-
eters are obtained by static or dynamic visualization and 
mapping. 
18. The method of claim 1, further comprising generating 
and repeatedly updating the fluid-solid interaction biome-
chanical model, performing a biomechanics simulation, gen-
erating biomechanics data, and analyzing the simulation and 
biomechanics data to optimize the proposed treatment option. 
19. The method of claim 1, further comprising computing 
mean patient data based on patient data for a plurality of 
patients. 
20. A method for analyzing and predicting treatment out-
comes of vascular interventions and reconstructions, com-
prising: 
obtaining, in vivo, patient specific data associated with a 
patient; 
searching a database and obtaining additional data to be 
associated with the patient, wherein the database is con-
figured to classify and stored data for a plurality of 
patients, and wherein the additional data is obtained 
based at least in part on patient specific data stored 
within the database for one or more other patients; 
selecting at least one of a treatment parameter or medical 
device parameter to be used in association with a pro-
posed treatment option for treating the patient; 
searching the database and obtaining one or more model 
properties associated with the treatment parameter or 
medical device parameter; 
generating a fluid-solid interaction biomechanical model 
based at least in part on the patient specific data, the 
additional data associated with the patient, and the 
model properties, wherein the fluid-solid interaction 
biomechanical model comprises time-dependent, three-
dimensional solid and fluid equations; 
performing a biomechanics simulation and generating bio-
mechanics data using the biomechanical model; and 
analyzing the biomechanics data and determining the 
effectiveness of the proposed treatment. 
21. A system for analyzing and predicting therapeutic out-
comes in medical procedures, comprising: 
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a relational database configured for classifYing and storing 
patient specific input data for a plurality of patients; 
a means for obtaining and inputting patient specific input 
data to the database; 
a means for selecting additional data to be associated with 
the patient in the database; 
a means for inputting treatment related and medical device 
related parameters to the database; 
a means for selecting treatment type, inputting model 
parameters, and assembling a biomechanical model 
based on the selected treatment type, the patient specific 
data, the additional data associated with the patient, and 
the treatment and medical device related parameters; 
a processor and fluid-solid interaction biomechanical 
model configured for performing a biomechanics simu-
lation and generating biomechanics data, the fluid-solid 
biomechanical model comprising time-dependent, 
three-dimensional solid and fluid equations; 
a means for evaluating the outcomes of the biomechanics 
simulation; and 
an interface configured for exchanging data between the 
database and a plurality of users. 
22. The system of claim 21, wherein said means for gath-
ering input data comprises a plurality of input evaluation 
modules. 
23. The system of claim 22, wherein the plurality of evalu-
ation modules are selected from the group of modules com-
prising a mechanical properties evaluation module, a blood 
rheology evaluation module, a blood vessel geometry evalu-
ation module, a medical device geometry evaluation module, 
a boundary blood flow evaluation module, and a load evalu-
ation module. 
24. The system of claim 22, wherein the plurality of evalu-
ation modules further comprises a restenosis prediction mod-
ule. 
25. The system of claim 22, wherein the plurality of evalu-
ation modules further comprises a failure prediction module. 
26. The system of claim 22, wherein the plurality of evalu-
ation modules further comprises a treatment selection and 
optimization module. 
27. The system of claim 22, wherein the plurality of evalu-
ation modules further comprises a design evaluation module. 
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